BioDelivery Sciences International Stock News

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) saw some unusual options trading on Wednesday. Traders purchased 5,050 call options on the stock. This is an increase of approximately 450% compared to the average volume of 918 call options. In other news, Director Mark A. Sirgo bought 18,587 shares of the businesss stock in a transaction on Thursday, []

The Opioid Use Disorder Market report aims to convey an inexpensive understanding of the business which has been analyzed by using primary and secondary research strategies. the main purpose of this Opioid Use Disorder Market report is to supply an

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock?

State Street Corp grew its position in shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) by 15.5% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,289,355 shares of the specialty pharmaceutical companys stock after acquiring an additional 307,538 shares during the []

Northern Trust Corp reduced its position in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) by 2.2% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 1,009,589 shares of the specialty pharmaceutical companys stock after selling 22,627 shares during the quarter. Northern Trust Corps holdings in BioDelivery Sciences International were worth []

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Kevin Kotler acquired 100,000 shares of the businesss stock in a transaction dated Friday, November 19th. The shares were bought at an average cost of $3.06 per share, for a total transaction of $306,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through []

Wall Street brokerages predict that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will report earnings of ($0.02) per share for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for BioDelivery Sciences Internationals earnings. The highest EPS estimate is $0.04 and the lowest is ($0.04). BioDelivery Sciences International reported earnings of $0.10 per share []

Wall Street brokerages expect that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will post $41.59 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for BioDelivery Sciences International’s earnings. The highest sales estimate is $41.90 million and the lowest is $41.29 million. BioDelivery Sciences International posted sales of $42.17 million […]

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Mark A. Sirgo bought 16,000 shares of the stock in a transaction dated Thursday, November 11th. The shares were purchased at an average cost of $3.20 per share, for a total transaction of $51,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which []

Are these Reddit penny stocks on your watchlist right now? The post Best Reddit Penny Stocks to Buy Now?

BioDelivery Sciences International's (BDSI) CEO Jeff Bailey on Q3 2021 Results -Earnings Call Transcript

BioDelivery (BDSI) delivered earnings and revenue surprises of 16.67% and -2.28%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.